Pathologists play an increasingly important role in personalized medicine for patients with lung cancer as a result of the newly recognized relationship between histologic classification and molecular change. In 2011, the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) proposed a new architectural classification for invasive lung adenocarcinomas to provide uniform terminology and diagnostic criteria. This review highlighted the evolution of the classification of lung adenocarcinomas in resected specimens with special respect to both histologic subtyping and invasion. Histologic subtyping of lung adenocarcinoma has been updated based on five major predominant patterns. New concepts of adenocarcinoma in situ and minimally invasive adenocarcinomas have been introduced to define the condition of patients who are expected to have excellent survival. Although the new IASLC/ATS/ERS classification has promising clinical relevance, significant clarification remains necessary for the definitions of subtyping and invasion. More precise definitions and subsequent better education on the interpretation of terminology will be helpful for future studies.

Citations

Citations to this article as recorded by  

• Radiomics for Classifying Histological Subtypes of Lung Cancer Based on Multiphasic Contrast-Enhanced Computed Tomography
  Linning E, Lin Lu, Li Li, Hao Yang, Lawrence H. Schwartz, Binsheng Zhao
  Journal of Computer Assisted Tomography.2019; 43(2): 300.     CrossRef
• Tumor heterogeneity assessed by texture analysis on contrast-enhanced CT in lung adenocarcinoma: association with pathologic grade
  Ying Liu, Shichang Liu, Fangyuan Qu, Qian Li, Runfen Cheng, Zhaoxiang Ye
  Oncotarget.2017; 8(32): 53664.     CrossRef
• Clinicopathological and prognostic significance of metastasis-associated protein 1 expression and its correlation with angiogenesis in lung invasive adenocarcinomas, based on the 2011 IASLC/ATS/ERS classification
  SHUHAI LI, HUI TIAN, WEIMING YUE, LIN LI, CUN GAO, LIBO SI, WENSI HU, LEI QI, MING LU, CHUANLE CHENG, JINGJING CUI, GUANQING CHEN
  Oncology Letters.2016; 11(1): 224.     CrossRef
• Myoferlin expression in non-small cell lung cancer: Prognostic role and correlation with VEGFR-2 expression
  DAE HYUN SONG, GYUNG HYUCK KO, JEONG HEE LEE, JONG SIL LEE, GYEONG-WON LEE, HYEON CHEOL KIM, JUNG WOOK YANG, ROK WON HEO, GU SEOB ROH, SUN-YOUNG HAN, DONG CHUL KIM
  Oncology Letters.2016; 11(2): 998.     CrossRef
• ROS1 gene rearrangement and copy number gain in non-small cell lung cancer
  Yan Jin, Ping-Li Sun, Hyojin Kim, Eunhyang Park, Hyo Sup Shim, Sanghoon Jheon, Kwhanmien Kim, Choon-Taek Lee, Jin-Haeng Chung
  Virchows Archiv.2015; 466(1): 45.     CrossRef
• The Demise of the Term Bronchioloalveolar Carcinoma
  Yasmeen M. Butt, Timothy Craig Allen
  Archives of Pathology & Laboratory Medicine.2015; 139(8): 981.     CrossRef
• Expression of EGFR and Molecules Downstream to PI3K/Akt, Raf-1-MEK-1-MAP (Erk1/2), and JAK (STAT3) Pathways in Invasive Lung Adenocarcinomas Resected at a Single Institution
  Alba Fabiola Torres, Cleto Nogueira, Juliana Magalhaes, Igor Santos Costa, Alessa Aragao, Antero Gomes Neto, Filadelfia Martins, Fabio Tavora
  Analytical Cellular Pathology.2014; 2014: 1.     CrossRef
• Usual Interstitial Pneumonia with Lung Cancer: Clinicopathological Analysis of 43 Cases
  Dae Hyun Song, In Ho Choi, Sang Yun Ha, Kang Min Han, Jae Jun Lee, Min Eui Hong, Kyeongman Jeon, Man Pyo Chung, Jhingook Kim, Joungho Han
  Korean Journal of Pathology.2014; 48(1): 10.     CrossRef
• Cytoplasmic YAP Expression is Associated with Prolonged Survival in Patients with Lung Adenocarcinomas and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment
  Ping-Li Sun, Ji Eun Kim, Seol Bong Yoo, Hyojin Kim, Yan Jin, Sanghoon Jheon, Kwhanmien Kim, Choon Taek Lee, Jin-Haeng Chung
  Annals of Surgical Oncology.2014; 21(S4): 610.     CrossRef